PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 17 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

3 March 2026

  1. (diff | hist) m 19:38 Glucose-dependent insulinotropic polypeptide 8,265 ±0 AmylinAmos (talk | contribs) clarify that the receptor is expressed outside the pancreas [rollback]
  2. (diff | hist) 18:19 Amylin 5,795 ±0 KPV_Kester (talk | contribs) rm duplicated pharmacokinetics — the same figures appear in the infobox [rollback]
  3. (diff | hist) m 15:00 Glucagon-like peptide-1 12,294 ±0 GsCouplingGil (talk | contribs) attribute the receptor-density claim to the tissue study it comes from [rollback]
  4. (diff | hist) m 14:53 Third-party testing 7,489 ±0 LedgerLysander (talk | contribs) ce [rollback]
  5. (diff | hist) m 12:39 Liraglutide 5,967 ±0 CagriCass (talk | contribs) add the molecular formula to the infobox [rollback]
  6. (diff | hist) m 11:00 Sarcopenia 4,491 ±0 GHK_Gwendolen (talk | contribs) add the paediatric interval with the caveat that it differs [rollback]
  7. (diff | hist) 10:17 Dose escalation schedule 4,993 ±0 StabilityStig (talk | contribs) ce [rollback]
  8. (diff | hist) m 09:26 Chinese Peptide Company 15,513 ±0 EndotoxinEd (talk | contribs) expand §Reception [rollback]
  9. (diff | hist) 09:11 Talk:Lyophilisation 1,370 +168 UnitAuditUwe (talk | contribs) /* Worked sublimation example: single vial or batch? */ reply
  10. (diff | hist) 08:10 Talk:Retatrutide 822 +167 PreregPriya (talk | contribs) /* Phase 2 figures in the lead */ reply

2 March 2026

  1. (diff | hist) 16:29 Fmoc chemistry 4,618 ±0 AnalyticalAnnie (talk | contribs) clarify that the cake appearance is an indicator, not a specification [rollback]
  2. (diff | hist) 15:12 Talk:Peptide stability table 1,244 +272 PrimarySrcPatia (talk | contribs) /* Sourcing of the reconstituted-stability column */ reply
  3. (diff | hist) 14:52 Talk:Lyophilisation 1,159 +326 ColdChainCleo (talk | contribs) /* Worked sublimation example: single vial or batch? */ reply
  4. (diff | hist) 14:00 Talk:Limit of detection 611 +158 COA_Colwyn (talk | contribs) /* The inverted reading */ reply
  5. (diff | hist) 13:50 Talk:SUSTAIN trial programme 611 +141 SafetySignalSid (talk | contribs) /* Retinopathy finding */ reply
  6. (diff | hist) 13:25 Talk:Retention time 611 +69 GradientGus (talk | contribs) /* Dwell volume */ reply
  7. (diff | hist) 12:40 Talk:Retatrutide 611 +145 RetatrutideRuben (talk | contribs) /* Phase 2 figures in the lead */ reply
  8. (diff | hist) 12:29 Custom peptide synthesis 4,773 ±0 SupplyWatchSuri (talk | contribs) state the difference between a validated shipper and an insulated box [rollback]
  9. (diff | hist) 12:15 Talk:Lyophilisation 948 +291 PlainNumbersPip (talk | contribs) /* Worked sublimation example: single vial or batch? */ new section
  10. (diff | hist) 11:32 Medutest 5,018 ±0 EmptyingElke (talk | contribs) add the chain-of-custody point to §Limitations [rollback]
  11. (diff | hist) 11:19 Qingdao Saber Technology Pharmaceutical 14,372 +642 LeanMassLars (talk | contribs) expand §Notability and coverage [rollback]
  12. (diff | hist) 10:25 Talk:Limit of detection 400 +155 LOD_Lorcan (talk | contribs) /* The inverted reading */ new section
  13. (diff | hist) 10:15 Talk:SUSTAIN trial programme 400 +172 RetinopathyRex (talk | contribs) /* Retinopathy finding */ new section
  14. (diff | hist) 09:50 Talk:Retention time 400 +149 Retention_Time_Rae (talk | contribs) /* Dwell volume */ new section
  15. (diff | hist) 09:25 Talk:Retatrutide 400 +171 PreregPriya (talk | contribs) /* Phase 2 figures in the lead */ new section
  16. (diff | hist) 01:06 Dual incretin agonist 5,851 ±0 MTC_Marisol (talk | contribs) add the discontinued indication with its date [rollback]

1 March 2026

  1. (diff | hist) m 22:57 PolyPeptide Group (Hangzhou) 17,648 +226 LyophilLena (talk | contribs) add the minimum order quantity for custom synthesis [rollback]
  2. (diff | hist) 20:42 Proglucagon 6,709 ±0 SemaglutideSasha (talk | contribs) move the trial material out of §Physiology into the compound articles [rollback]
  3. (diff | hist) 19:50 Tianjin Finder Chemical 14,449 ±0 SecretagogueSol (talk | contribs) sentence case in headings per PP:MOS [rollback]
  4. (diff | hist) m b 17:43 Deamidation 5,263 ±0 StubSorterBot (talk | contribs) bot: normalise unit spacing [rollback]
  5. (diff | hist) m 14:49 Counterfeit peptide 5,488 ±0 Chromatokid (talk | contribs) space between number and unit per PP:MOS [rollback]
  6. (diff | hist) 09:59 ChinaPeptides 14,979 ±0 VerifyVesna (talk | contribs) rm the price; supplier articles carry no price per PP:VN [rollback]
  7. (diff | hist) m b 00:52 Amylin receptor agonist 5,245 ±0 StubSorterBot (talk | contribs) bot: repair redlinked category [rollback]

28 February 2026

  1. (diff | hist) 13:50 Talk:Arcuate nucleus 611 +171 ArcuateArt (talk | contribs) /* Inverse agonism at MC4R */ reply
  2. (diff | hist) 13:40 Talk:Repackaging 611 +110 LotTraceLuka (talk | contribs) /* Retaining the original identifier */ reply
  3. (diff | hist) 11:50 Talk:Enteroendocrine L cell 885 +216 Ref_Desk_Ron (talk | contribs) /* Plasticity section: obesity claim needs updating */ reply
  4. (diff | hist) 10:18 Liquid chromatography-mass spectrometry 4,463 ±0 RegainRomilly (talk | contribs) add the counterion determination method by name [rollback]
  5. (diff | hist) 10:15 Talk:Arcuate nucleus 400 +226 MelanocortinMil (talk | contribs) /* Inverse agonism at MC4R */ new section
  6. (diff | hist) 10:05 Talk:Repackaging 400 +162 RepackRadek (talk | contribs) /* Retaining the original identifier */ new section
  7. (diff | hist) 09:22 Talk:Enteroendocrine L cell 674 +252 Peptide_Pete (talk | contribs) /* Plasticity section: obesity claim needs updating */ new section
  8. (diff | hist) m 08:18 Vial 26,012 ±0 Chromatokid (talk | contribs) fix hyphenation per PP:MOS [rollback]
  9. (diff | hist) 03:21 Lot traceability 5,317 ±0 LedgerLysander (talk | contribs) split §What a report shows from §What it does not [rollback]

27 February 2026

  1. (diff | hist) m 23:22 Methionine oxidation 5,001 ±0 TechnicianTeal (talk | contribs) add the forced-degradation conditions the claim rests on [rollback]
  2. (diff | hist) 22:45 Exenatide 5,754 ±0 GradientGus (talk | contribs) ce, tighten prose [rollback]
  3. (diff | hist) 21:29 Patent expiry and biosimilars 4,553 ±0 ImportRecordIna (talk | contribs) add the telehealth prescribing point as attributed [rollback]
  4. (diff | hist) 16:46 Reference standard 5,217 ±0 PeakShapePol (talk | contribs) clarify that area percent is not mass percent [rollback]
  5. (diff | hist) 13:20 Talk:GLP-1 receptor 959 +124 HedgeHedda (talk | contribs) /* Bias section overstates the therapeutic case */ reply
  6. (diff | hist) 13:15 Talk:Missed dose 611 +156 LabelLibby (talk | contribs) /* Not a substitute for labelling */ reply
  7. (diff | hist) 13:15 Talk:Receptor bias 611 +101 PuffRemoverPax (talk | contribs) /* Productive research, disappointing translation */ reply
  8. (diff | hist) 11:44 Talk:GLP-1 receptor 748 +139 GsCouplingGil (talk | contribs) /* Bias section overstates the therapeutic case */ reply
  9. (diff | hist) 09:40 Talk:Missed dose 400 +164 MissedDoseMik (talk | contribs) /* Not a substitute for labelling */ new section
  10. (diff | hist) 09:40 Talk:Receptor bias 400 +148 GsCouplingGil (talk | contribs) /* Productive research, disappointing translation */ new section
  11. (diff | hist) 09:05 Talk:GLP-1 receptor 537 +167 HedgeHedda (talk | contribs) /* Bias section overstates the therapeutic case */ new section
  12. (diff | hist) m 07:40 Sigma-Aldrich (Shanghai) Trading 18,641 +220 HyphenHarriet (talk | contribs) expand §Reception [rollback]
  13. (diff | hist) m 07:12 GenScript Peptides 16,483 +798 FmocFrancis (talk | contribs) expand §Product range [rollback]
  14. (diff | hist) 03:58 Wuhan Wansheng Biotechnology 15,849 ±0 ToleranceTove (talk | contribs) de-orphan [rollback]
  15. (diff | hist) 03:43 Hubei Jianxiang Bioscience 14,855 ±0 BaselineBex (talk | contribs) add the incorporation year, attributed to the registry record [rollback]

26 February 2026

  1. (diff | hist) m 23:04 Timeline of incretin therapeutics 4,460 ±0 SemaglutideSasha (talk | contribs) expand §Second generation and beyond [rollback]
  2. (diff | hist) m 19:49 Bacterial endotoxin test 5,317 ±0 IncretinIvo (talk | contribs) add the reference standard and its traceability [rollback]
  3. (diff | hist) 19:46 Retention time 4,104 ±0 AAA_Analyst (talk | contribs) expand §Reporting on certificates [rollback]
  4. (diff | hist) 16:31 Aspiration risk under anaesthesia 4,681 ±0 GsCouplingGil (talk | contribs) expand §Interpretation [rollback]
  5. (diff | hist) 13:25 Talk:Patent expiry and biosimilars 611 +111 Chromatokid (talk | contribs) /* Impurities carry the application */ reply
  6. (diff | hist) 12:40 Talk:Underfilling 611 +85 PlainNumbersPip (talk | contribs) /* The arithmetic paragraph */ reply
  7. (diff | hist) 09:50 Talk:Patent expiry and biosimilars 400 +161 BiosimilarBoaz (talk | contribs) /* Impurities carry the application */ new section
  8. (diff | hist) 09:15 Talk:Underfilling 400 +189 UnderfillUna (talk | contribs) /* The arithmetic paragraph */ new section
  9. (diff | hist) 06:41 Growth hormone secretagogue 4,613 ±0 CouplingCillian (talk | contribs) state the research-use-only status in the lead, not only in the footer [rollback]
  10. (diff | hist) 05:48 Trial data comparison 7,303 ±0 TitrationTheo (talk | contribs) add category for interactive reference tools [rollback]
  11. (diff | hist) 05:03 Reconstitution of lyophilised peptides 5,761 ±0 BUD_Bertram (talk | contribs) add a second worked example at a different vial strength [rollback]

25 February 2026

  1. (diff | hist) m 14:57 Research use only 7,990 ±0 DrTitration (talk | contribs) convert the jurisdiction comparison to a table [rollback]
  2. (diff | hist) 14:12 Talk:Dual incretin agonist 748 +161 Hedgerow_Hal (talk | contribs) /* Numbered list in the middle section */ reply
  3. (diff | hist) 13:40 Talk:Deamidation 611 +105 AAA_Analyst (talk | contribs) /* Isoaspartate is invisible to mass */ reply
  4. (diff | hist) 13:25 Talk:LEADER trial 611 +116 FlowTrialFraser (talk | contribs) /* Renal signal was a marker */ reply
  5. (diff | hist) 12:49 AmbioPharm 15,052 +433 ListMakerLumi (talk | contribs) label the reception tally as weak, self-selected evidence at this point of use [rollback]
  6. (diff | hist) 10:40 Talk:Dual incretin agonist 537 +182 ManualOfStyleMo (talk | contribs) /* Numbered list in the middle section */ new section
  7. (diff | hist) m 10:21 Peptide supply chain 8,410 ±0 ThymosinTamsin (talk | contribs) add the cross-link to the temperature-excursion article [rollback]
  8. (diff | hist) 10:05 Talk:Deamidation 400 +169 MassSpecMarv (talk | contribs) /* Isoaspartate is invisible to mass */ new section
  9. (diff | hist) 09:50 Talk:LEADER trial 400 +157 eGFR_Esme (talk | contribs) /* Renal signal was a marker */ new section
  10. (diff | hist) 07:10 SinoPep 18,140 +1,342 BlankVialBo (talk | contribs) state which lines are held in regional stock [rollback]
  11. (diff | hist) 07:09 Guangzhou JEEP Biotechnology 15,452 ±0 AmylinAmos (talk | contribs) add category for suppliers in China [rollback]
  12. (diff | hist) m 06:51 Prescribing information 4,506 ±0 Chromatokid (talk | contribs) add the prior-authorisation criterion as attributed to the payer document [rollback]
  13. (diff | hist) m b 05:57 Blind sampling 8,193 ±0 StubSorterBot (talk | contribs) bot: normalise citation format [rollback]
  14. (diff | hist) m 04:47 Shanghai ERP Biotechnology 14,417 ±0 SecondarySrc_Seb (talk | contribs) split §Operations from §Product range [rollback]

24 February 2026

  1. (diff | hist) 22:27 CagriSema 5,687 ±0 RetatrutideRuben (talk | contribs) give the INN alongside the trade name at first mention [rollback]
  2. (diff | hist) m 18:38 Electrospray ionisation 4,323 ±0 TFA_Counterion (talk | contribs) add category for method validation [rollback]
  3. (diff | hist) m 16:45 Xi'an Mokemei Biotechnology 15,421 ±0 FreightFenna (talk | contribs) move a stray full stop inside the reference [rollback]
  4. (diff | hist) 13:40 Talk:PeptideMeter 611 +213 ForestPlotFinn (talk | contribs) /* Lower bound on variability */ reply
  5. (diff | hist) 13:15 Talk:Fasting insulin 611 +96 HOMA_Hettie (talk | contribs) /* Four combinations */ reply
  6. (diff | hist) 11:10 Talk:Beyond-use date 1,666 +382 Ref_Desk_Ron (talk | contribs) /* RfC: are beyond-use date and expiration date being conflated across the wiki? */ reply
  7. (diff | hist) 10:15 Talk:PeptideMeter 400 +200 TallySheetTad (talk | contribs) /* Lower bound on variability */ new section
  8. (diff | hist) 09:40 Talk:Fasting insulin 400 +138 PanelPlannerPam (talk | contribs) /* Four combinations */ new section
  9. (diff | hist) m 05:13 Bachem Holding (Suzhou) 15,124 ±0 VerifyVesna (talk | contribs) copyedit [rollback]

23 February 2026

  1. (diff | hist) m b 07:45 Beyond-use date 23,171 ±0 StubSorterBot (talk | contribs) bot: normalise citation format [rollback]
  2. (diff | hist) m 06:52 Shanghai Sigma-Audley New Material Technology 15,579 ±0 FlowTrialFraser (talk | contribs) add the standing talk-page note link to the banner [rollback]
  3. (diff | hist) m 06:31 International nonproprietary name 4,356 ±0 eGFR_Esme (talk | contribs) add the molecular formula to the infobox [rollback]

22 February 2026

  1. (diff | hist) 19:46 Melanotan II 4,649 ±0 ITT_Imelda (talk | contribs) de-orphan [rollback]
  2. (diff | hist) 16:55 Lixisenatide 4,195 ±0 RetatrutideRuben (talk | contribs) add the excipient list from the labelling [rollback]
  3. (diff | hist) 13:10 Talk:Subcutaneous injection 611 +151 HalfLifeHavel (talk | contribs) /* Extrapolating insulin site data */ reply
  4. (diff | hist) 10:17 Hunan Aslsen Technology 15,492 ±0 COA_Colwyn (talk | contribs) ce, tighten prose [rollback]
  5. (diff | hist) 10:05 Talk:Test report forgery 822 +151 CitationChaser (talk | contribs) /* Sourcing of the forgery-pattern material */ reply
  6. (diff | hist) 09:35 Talk:Subcutaneous injection 400 +182 SubQ_Solveig (talk | contribs) /* Extrapolating insulin site data */ new section